A Phase 2B, 8-week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults With DSM5 Current Cannabis Use Disorder (CUD)
Phase of Trial: Phase II
Latest Information Update: 19 Aug 2019
Price : $35 *
At a glance
- Drugs PF 4457845 (Primary)
- Indications Psychiatric disorders
- Focus Therapeutic Use
- Acronyms FAAH-I MULTI
- 15 Aug 2019 Planned number of patients changed from 260 to 237.
- 15 Aug 2019 Status changed from active, no longer recruiting to recruiting.
- 19 Jul 2019 Status changed from not yet recruiting to active, no longer recruiting.